Erasca, Inc.
A clinical-stage biopharmaceutical company developing medicines for cancers driven by the RAS/MAPK pathway, one of the most frequently mutated signaling routes in human tumors. Founded in San Diego in 2018, its name blends "RAS" with "era," reflecting a mission to open a new era in treating RAS-driven cancers. The company is building a pipeline of experimental drugs aimed at this stubborn family of cancer-causing proteins.
Granted 203.9K · Sold 200.0K
Granted 20.0K · Sold 20.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Chacko David M.CFO and CBO · 1 transaction | +6.8% | 280.0K | — | — | — |
| Garner EbunChief Legal Officer · 5 transactions | +396.3% | 105.1K | 203.9K | — | 200.0K |
| Morris ShannonChief Medical Officer · 2 transactions | — | 20.0K | 20.0K | — | 20.0K |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last year: -220.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.